Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Fluorescent visualization of Src by using dasatinib-BODIPY.

Vetter ML, Zhang Z, Liu S, Wang J, Cho H, Zhang J, Zhang W, Gray NS, Yang PL.

Chembiochem. 2014 Jun 16;15(9):1317-24. doi: 10.1002/cbic.201402010. Epub 2014 May 14.

2.

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.

Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):531-8. doi: 10.1016/j.jtcvs.2012.10.041. Epub 2012 Nov 9.

3.

Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.

Cai J, Sun M, Wu X, Chen J, Wang P, Zong X, Ji M.

Eur J Med Chem. 2013 May;63:702-12. doi: 10.1016/j.ejmech.2013.03.013. Epub 2013 Mar 16.

PMID:
23567960
4.

An update on dual Src/Abl inhibitors.

Musumeci F, Schenone S, Brullo C, Botta M.

Future Med Chem. 2012 Apr;4(6):799-822. doi: 10.4155/fmc.12.29. Review.

PMID:
22530642
5.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.

Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636.

6.

Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging.

Nobis M, McGhee EJ, Herrmann D, Magenau A, Morton JP, Anderson KI, Timpson P.

Cell Adh Migr. 2014;8(5):478-86. doi: 10.4161/19336918.2014.970004.

7.

Role of Src tyrosine kinases in experimental pulmonary hypertension.

Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1354-65. doi: 10.1161/ATVBAHA.112.248500. Epub 2012 Apr 19.

8.

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH.

Oncogene. 2010 Jun 3;29(22):3196-207. doi: 10.1038/onc.2010.73. Epub 2010 Mar 15.

9.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

10.

Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.

PMID:
21751967
11.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

12.

SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Tokuhisa Y, Lidsky ME, Toshimitsu H, Turley RS, Beasley GM, Ueno T, Sharma K, Augustine CK, Tyler DS.

Ann Surg Oncol. 2014 Mar;21(3):1024-30. doi: 10.1245/s10434-013-3387-6. Epub 2013 Nov 27.

13.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

14.
15.

Current status of SRC inhibitors in solid tumor malignancies.

Puls LN, Eadens M, Messersmith W.

Oncologist. 2011;16(5):566-78. doi: 10.1634/theoncologist.2010-0408. Epub 2011 Apr 26. Review.

16.

Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB.

Mol Cancer Ther. 2010 Aug;9(8):2322-32. doi: 10.1158/1535-7163.MCT-09-1212. Epub 2010 Aug 3.

17.

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.

Cancer Res. 2006 Jan 1;66(1):473-81.

18.

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ.

Breast Cancer Res Treat. 2007 Nov;105(3):319-26. Epub 2007 Feb 1.

PMID:
17268817
19.

Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.

Hingorani P, Zhang W, Gorlick R, Kolb EA.

Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657. Epub 2009 May 15.

20.

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.

Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971.

Supplemental Content

Support Center